Company’s Next Brain Cancer Drug Likely to Come from Marijuana

Glioblastoma Multiforme is a devastating form of brain cancer. Most patients don’t survive two years after diagnosis. But, UK-based GW Pharmaceuticals is conducting a study that, thus far, suggests that using a CBD- and THC-based drug may increase the life expectancy of Glioblastoma Multiforme sufferers.

An experimental concoction of CBD and THC seems to increase life expectancy by roughly six months, according to Fortune.  The study is only mid-stage, but scientists have started interpreting the data and have received promising information showing that marijuana may be the answer to fighting some forms of brain cancer.

CEO Justin Gover said, “We believe the signals of efficacy demonstrated in this study further reinforce the potential role of cannabinoids in the field of oncology and provide GW with the prospect of a new and distinct cannabinoid product candidate in the treatment of glioma.”

The drug used in the study was created by GW Pharmaceuticals and is a concentrated form of CBD and THC.

Due to federal laws, the marijuana research being conducted in the UK and Israel far exceeds those in the U.S.